title: mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.
abstract: Monoclonal therapies could represent baseline-personalized medicine for patients with neoplasia. One of the most successful examples is Trastuzumab, a humanized antibody against epidermal growth factor receptor 2. Human epidermal growth factor receptor 2 (HER2) is a trans-membrane tyrosine kinase coded by the gene HER2/neu and overexpressed in approximately 12% to 20% of infiltrating breast carcinomas. The overexpression of HER2 is an independent adverse prognostic factor in relation to survival and is also predictive of response to treatment. Therefore, the correct evaluation of HER2 status is essential for the management of infiltrating breast carcinoma to determine the response to Trastuzumab. The most common evaluation technique is immunohistochemistry, which is confirmed by fluorescent or chromogenic monochrome or dual-gene in situ hybridization in ambiguous cases (immunohistochemical 2+). Our objective was to evaluate the diagnostic value of a new technique on the basis of HER2 mRNA in situ hybridization (HistoSonda) and study its correlation with immunohistochemistry and dual-chromogenic in situ hybridization (DUO-CISH) in 403 cases of infiltrating breast carcinoma. The percentage of DUO-CISH amplification was 25.8%, HistoSonda positivity was 31.2%, and positivity for Hercep-Test was 48.1%, including (+2) and (+3). Comparisons were made of each of the techniques, HistoSonda to IHQ and HistoSonda to DUO-CISH. The overall concordance between DUO-CISH and HistoSonda was 89%. Our data support the consistency of HistoSonda as a useful tool to determine HER2 status in breast cancer.
authors.affiliation: Department of Pathology, Hospital Lluís Alcanyis, Xàtiva, Spain. bernet_lai@gva.es
authors.forename: Laia
authors.initials: L
authors.lastname: Bernet
authors.forename: Marcos
authors.initials: M
authors.lastname: Martinez Benaclocha
authors.forename: Carles
authors.initials: C
authors.lastname: Castera
authors.forename: Rafael
authors.initials: R
authors.lastname: Cano Muñoz
authors.forename: Francisco
authors.initials: F
authors.lastname: Sevilla
authors.forename: Javier
authors.initials: J
authors.lastname: Alba
authors.forename: Juan
authors.initials: J
authors.lastname: de Dios Barranco
authors.forename: Alicia
authors.initials: A
authors.lastname: Cordoba
authors.forename: Tomas
authors.initials: T
authors.lastname: Garcia-Caballero
authors.forename: David
authors.initials: D
authors.lastname: Hardisson
authors.forename: Javier Martin
authors.initials: JM
authors.lastname: de Francisco Hernandez
authors.forename: Jose Miguel
authors.initials: JM
authors.lastname: Lazaro
authors.forename: Luis
authors.initials: L
authors.lastname: Polo
authors.forename: Francesc
authors.initials: F
authors.lastname: Riu
authors.forename: Ricardo
authors.initials: R
authors.lastname: Rezola
authors.forename: Federico
authors.initials: F
authors.lastname: Rojo
authors.forename: Irune
authors.initials: I
authors.lastname: Ruiz
authors.forename: Ainoha
authors.initials: A
authors.lastname: Hernándiz
authors.forename: J M
authors.initials: JM
authors.lastname: de la Cámara de Las Heras
authors.forename: Victoria M
authors.initials: VM
authors.lastname: Coupe
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000378:metabolism; D003951:Diagnostic Errors; D005260:Female; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods*; D025202:Molecular Diagnostic Techniques; D011446:Prospective Studies; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D012189:Retrospective Studies; D013030:Spain
chemical_list: D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human